Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5081 Target Snapshot

Interleukin-1 receptor-associated kinase 3 · SINGLE PROTEIN · Homo sapiens

502Compounds
126Assays
10Approved Drugs
405.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9Y616. Use UniProt Q9Y616 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9Y616 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Interleukin-1 receptor-associated kinase 3 as ChEMBL target CHEMBL5081, mapped to UniProt Q9Y616. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Interleukin-1 receptor-associated kinase 3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5081
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9Y616
Interleukin-1 receptor-associated kinase 3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Interleukin-1 receptor-associated kinase 3 is the right protein anchor across sources, using UniProt Q9Y616 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelInterleukin-1 receptor-associated kinase 3
UniProt AccessionQ9Y616
Component TypeProtein
Sequence Length596 aa

Interleukin-1 receptor-associated kinase 3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Interleukin-1 receptor-associated kinase 3, mapped to UniProt Q9Y616. Sequence length is 596 aa.

Mapped IDQ9Y616
Review nameInterleukin-1 receptor-associated kinase 3
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

10
Approved
3
Phase III
11
Phase II
11
Phase I
Assay Mix

Activity Type Distribution

IC5035.0
KD370.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4763746 8.4 IC50 4.0 Preclinical
CHEMBL4788568 8.4 IC50 4.0 Preclinical
CHEMBL4749646 8.3 IC50 5.0 Preclinical
CHEMBL4744403 8.22 IC50 6.0 Preclinical
CHEMBL4777817 8.22 IC50 6.0 Preclinical
CHEMBL4798668 8.22 IC50 6.0 Preclinical
CHEMBL3301622 8.15 Kd 7.0 Approved
CHEMBL4094760 8.0 IC50 10.0 Preclinical
CHEMBL4779593 8.0 IC50 10.0 Preclinical
CHEMBL475251 7.96 Kd 11.0 Clinical
Distribution

pChEMBL Value Distribution

9
5.0
19
5.5
24
6.0
10
6.5
11
7.0
22
7.5
9
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

PACRITINIB
CHEMBL2035187
Approved 2022
FEDRATINIB
CHEMBL1287853
Approved 2019
GILTERITINIB
CHEMBL3301622
Approved 2018
MIDOSTAURIN
CHEMBL608533
Approved 2017
CRIZOTINIB
CHEMBL601719
Approved 2011
PAZOPANIB
CHEMBL477772
Approved 2009
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

126
Total Assays
89
Tested Compounds
1
Assay Types
Binding — 126 assays, 89 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 81 34 6.2
assay format 27 4 6.3
subcellular format 13 27 6.5
cell-based format 5 24 7.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine